Christopher R. Loose - Aug 17, 2022 Form 4 Insider Report for Frequency Therapeutics, Inc. (FREQ)

Role
Chief Scientific Officer
Signature
/s/ James P. Abely, Attorney-in-Fact for Christopher R. Loose
Stock symbol
FREQ
Transactions as of
Aug 17, 2022
Transactions value $
$0
Form type
4
Date filed
8/19/2022, 04:04 PM
Previous filing
Jul 7, 2022
Next filing
Jan 27, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FREQ Stock Option Award +147K 147K Aug 17, 2022 Common Stock 147K $2.14 Direct F1, F2
transaction FREQ Stock Option Disposed to Issuer -147K -100% 0 Aug 17, 2022 Common Stock 147K $14.00 Direct F1, F2
transaction FREQ Stock Option Award +57.5K 57.5K Aug 17, 2022 Common Stock 57.5K $2.14 Direct F2, F3
transaction FREQ Stock Option Disposed to Issuer -57.5K -100% 0 Aug 17, 2022 Common Stock 57.5K $25.05 Direct F2, F3
transaction FREQ Stock Option Award +70K 70K Aug 17, 2022 Common Stock 70K $2.14 Direct F2, F4
transaction FREQ Stock Option Disposed to Issuer -70K -100% 0 Aug 17, 2022 Common Stock 70K $35.85 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable in equal monthly installments over a four year period commencing on November 2, 2019, and will be fully vested and exercisable on October 2, 2023.
F2 The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.
F3 The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2020, and will be fully vested and exercisable on January 1, 2024.
F4 The option vests and becomes exercisable in equal monthly installments over a four year period commencing on February 1, 2021, and will be fully vested and exercisable on January 1, 2025.